日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Validation of a prognostic nomogram for locally advanced oropharyngeal carcinoma treated with intensity-modulated radiotherapy with/without systemic therapy

验证用于预测局部晚期口咽癌患者接受调强放射治疗(伴或不伴全身治疗)预后的列线图

Bossi, P; Gili, R; Calza, S; Licitra, L; Maddalo, M; Bacigalupo, A; Belgioia, L; Cacicedo, J; Facchinetti, N; Garcia Castano, A; Oliva, M; Bonomo, P; Sanguineti, G; Franco, P; Argiris, A; Psyrri, A; Orlandi, E

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)

卡铂、紫杉醇、贝伐珠单抗联合或不联合西妥珠单抗(IMC-A12)治疗晚期非鳞状非小细胞肺癌患者的 II 期随机试验:ECOG-ACRIN 癌症研究组 (E3508) 的一项试验

Argiris, A; Lee, J W; Stevenson, J; Sulecki, M G; Hugec, V; Choong, N W; Saltzman, J N; Song, W; Hansen, R M; Evans, T L; Ramalingam, S S; Schiller, J H

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors

达沙替尼治疗复发性或转移性 c-KIT 表达腺样囊性癌和非腺样囊性恶性唾液腺肿瘤的 II 期试验

Wong, S J; Karrison, T; Hayes, D N; Kies, M S; Cullen, K J; Tanvetyanon, T; Argiris, A; Takebe, N; Lim, D; Saba, N F; Worden, F P; Gilbert, J; Lenz, H J; Razak, A R A; Roberts, J D; Vokes, E E; Cohen, E E W

Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer

一项针对局部晚期头颈癌患者的II期随机试验,比较了放射治疗、西妥昔单抗和培美曲塞联合或不联合贝伐珠单抗的疗效。

Argiris, A; Bauman, J E; Ohr, J; Gooding, W E; Heron, D E; Duvvuri, U; Kubicek, G J; Posluszny, D M; Vassilakopoulou, M; Kim, S; Grandis, J R; Johnson, J T; Gibson, M K; Clump, D A; Flaherty, J T; Chiosea, S I; Branstetter, B; Ferris, R L

Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.

对高危头颈癌切除患者进行术后放疗联合顺铂加帕尼单抗治疗的 II 期试验

Ferris R L, Geiger J L, Trivedi S, Schmitt N C, Heron D E, Johnson J T, Kim S, Duvvuri U, Clump D A, Bauman J E, Ohr J P, Gooding W E, Argiris A

Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials

人乳头瘤病毒在复发或转移性头颈癌中的预后意义:一项东部肿瘤协作组试验分析

Argiris, A; Li, S; Ghebremichael, M; Egloff, A M; Wang, L; Forastiere, A A; Burtness, B; Mehra, R

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck

西妥昔单抗和贝伐单抗:复发性或转移性头颈部鳞状细胞癌的临床前数据和 II 期试验

A Argiris, A P Kotsakis, T Hoang, F P Worden, P Savvides, M K Gibson, R Gyanchandani, G R Blumenschein Jr, H X Chen, J R Grandis, P M Harari, M S Kies, S Kim

Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer

培美曲塞联合西妥昔单抗及同步放疗治疗头颈癌患者的I期临床试验

Argiris, A; Karamouzis, M V; Smith, R; Kotsakis, A; Gibson, M K; Lai, S Y; Kim, S; Branstetter, B F; Shuai, Y; Romkes, M; Wang, L; Grandis, J R; Ferris, R L; Johnson, J T; Heron, D E

Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy

采用RECIST标准,对接受放化疗的局部晚期头颈癌患者进行PET-CT联合扫描与单独CT扫描的疗效评估

Passero, V A; Branstetter, B F; Shuai, Y; Heron, D E; Gibson, M K; Lai, S Y; Kim, S W; Grandis, J R; Ferris, R L; Johnson, J T; Argiris, A